10x Genomics acquired Spatial Transcriptomics Holdings AB for $38.6 million, a transaction completed in December 2018, structured as Stock acquisition with ongoing contingent/royalty payments tied to Spatial Transcriptomics and Visium product revenue (headline value not disclosed).
Spatial Transcriptomics Holdings AB operates in Spatial Genomics / Visium, is based in Stockholm, Sweden. Acquisition of Stockholm-based Spatial Transcriptomics, a pioneer in spatial genomics whose technology bridges microscopy and RNA sequencing to capture the whole transcriptome from an intact tissue section. The technology formed the foundation of 10x's Visium platform.
Add spatial context to single-cell analysis, enabling researchers to understand not only what is in a cell but how cells are organized relative to one another across oncology, neurology and immunology.
Foundational technology for the Visium Spatial Gene Expression platform; ongoing contingent and royalty payments tied to Visium revenue. Visium Spatial platform
We are thrilled to have the Spatial Transcriptomics team join forces with us. Now, researchers will not only be able to understand what is happening within a cell but also understand where cellular activities are happening in relation to one another.Serge Saxonov, CEO and co-founder of 10x Genomics
Spatial genomic sequencing is the next frontier. With today's news, 10x has once again proven its commitment to leading our field into the future and we are excited to be partnering to bring this technology to a wider base.Joakim Lundeberg, co-founder of Spatial Transcriptomics
Advisory firms were not disclosed for this transaction.